Search Site
  • 0
    My Cart

    Click Here to Find How Many Items You Have Added:)

    image loader

    Adding item(s) to cart......

Home >> Signaling Pathways >> Apoptosis >> PD-1/PD-L1 interaction

PD-1/PD-L1 interaction

Programmed death-1 (PD-1) is a receptor on T cells that has been shown to suppress activating signals from the T cell receptor when bound by either of its ligands, Programmed death-ligand 1 (PD-L1) or PD-L2. When PD-1 expressing T cells contact cells expressing its ligands, functional activities in response to antigenic stimuli, including proliferation, cytokine secretion, and cytotoxicity are reduced. PD-1/PD-Ligand interactions down regulate immune responses during resolution of an infection or tumor, or during the development of self tolerance.

Interference with the PD-1/PD-L1 interaction has also shown enhanced T cell activity in chronic infection systems. Chronic lymphocytic chorio meningitis virus infection of mice also exhibits improved virus clearance and restored immunity with blockade of PD-L1.

In addition to enhancing immunologic responses to chronic antigens, blockade of the PD-1/PD-L1 pathway has also been shown to enhance responses to vaccination, including therapeutic vaccination in the context of chronic infection.

Products for  PD-1/PD-L1 interaction

  1. Cat.No. Product Name Information
  2. GC50482 (D)-PPA 1 PD-1/PD-L1 interaction inhibitor (D)-PPA 1 Chemical Structure
  3. GC69009 (D)-PPA 1 TFA

    (D)-PPA 1 TFA is an anti-hydrolysis D-peptide antagonist. It is an effective PD-1/PD-L1 inhibitor with an affinity of 0.51 μM for binding to PD-1, and it works both in vitro and in vivo.

     (D)-PPA 1 TFA Chemical Structure
  4. GC74500 Acasunlimab

    GEN1046

     Acasunlimab (GEN1046) is a bispecific antibody (bsAb) targeting PD-L1 and 4-1BB. Acasunlimab Chemical Structure
  5. GC74501 Adebrelimab

    SHR-1316

     Adebrelimab (SHR-1316) is a humanized IgG4 monoclonal PD-L1 (PD-1/PD-L1) antibody. Adebrelimab Chemical Structure
  6. GC66337 Anti-Mouse PD-L1 Antibody Anti-Mouse PD-L1 Antibody (10F.9G2) is an IgG2b antibody inhibitor against mouse PD-L1 (CD274/B7-H1), and the host is rat (Rat). Anti-Mouse PD-L1 Antibody Chemical Structure
  7. GC74719 ASC-69

    APY69

     ASC-69 (APY69)is a potent and promising PD-1/PD-L1 small-molecule inhibitor. ASC-69 Chemical Structure
  8. GC32704 Atezolizumab (MPDL3280A) Atezolizumab, a specific monoclonal antibody against PD-L1, can inhibit the combination between PD-L1 and PD-1. Atezolizumab (MPDL3280A) Chemical Structure
  9. GC31719 Avelumab (Anti-Human PD-L1, Human Antibody) Avelumab (Anti-Human PD-L1, Human Antibody) is a fully human IgG1 anti-PD-L1 monoclonal antibody with potential antibody-dependent cell-mediated cytotoxicity. Avelumab (Anti-Human PD-L1, Human Antibody) Chemical Structure
  10. GC25160 BMS-1001 BMS-1001 is a potent inhibitor of PD-1/PD-L1 interaction with EC50 of 253 nM. BMS-1001 alleviates the inhibitory effect of the soluble PD-L1 on the T-cell receptor-mediated activation of T-lymphocytes. BMS-1001 Chemical Structure
  11. GC38740 BMS-1001 hydrochloride BMS-1001 hydrochloride is an orally active human PD-L1/PD-1 immune checkpoint inhibitor. BMS-1001 hydrochloride Chemical Structure
  12. GC31753 BMS-1166 (PD-1/PD-L1-IN1) BMS-1166 (PD-1/PD-L1-IN1) is a potent PD-1/PD-L1 immune checkpoint inhibitor. BMS-1166 (PD-1/PD-L1-IN1) Chemical Structure
  13. GC38131 BMS-1166 hydrochloride BMS-1166 hydrochloride is a potent PD-1/PD-L1 immune checkpoint inhibitor. BMS-1166 hydrochloride Chemical Structure
  14. GC16762 BMS-202

    PD-1/PD-L1 inhibitor 2

     BMS-202 is a nonpeptidic PD-1/PD-L1 complex inhibitor binding to PD-L1 and blocks human PD-1/PD-L1 interaction (IC50=53.6nM) to prevent cancer cells from escaping antitumor immune responses. BMS-202 Chemical Structure
  15. GC73331 BMS-37 BMS-37 is a PD-1/PD-L1 immune checkpoint inhibitor. BMS-37 Chemical Structure
  16. GC62682 BMSpep-57 hydrochloride BMSpep-57 hydrochloride is a potent and competitive macrocyclic peptide inhibitor of PD-1/PD-L1 interaction with an IC50 of 7.68?nM. BMSpep-57 hydrochloride binds to PD-L1 with Kds of 19 nM and 19.88 nM in MST and SPR assays, respectively. BMSpep-57 hydrochloride facilitates T cell function by in creasing IL-2 production in PBMCs. BMSpep-57 hydrochloride Chemical Structure
  17. GC68815 Budigalimab

    ABBV 181; PR 1648817

    Budigalimab (ABBV 181; PR 1648817) is a human IgG1 monoclonal antibody that targets the programmed cell death 1 (PD-1) receptor. Budigalimab has an Fc mutation, which reduces Fc receptor interactions and inhibitory effects of effector molecules.

     Budigalimab Chemical Structure
  18. GC74464 Cadonilimab

    AK104

     Cadonilimab (AK104) is a humanized tetravalent IgG1 bispecific antibody targeting PD1/CTLA4. Cadonilimab Chemical Structure
  19. GC62253 Camrelizumab

    SHR-1210

     Camrelizumab (also known as SHR-1210) is a high-affinity, humanized IgG4-κ monoclonal antibody. Camrelizumab Chemical Structure
  20. GC74305 CD24/Siglec-10 blocking peptide, CSBP CD24/Siglec-10 blocking peptide, CSBP can not only block the interaction of CD24/Siglec-10 but also PD-1/PD-L1. CD24/Siglec-10 blocking peptide, CSBP Chemical Structure
  21. GC74467 Cemiplimab Cemiplimab (Anti-Human PD-1) is a high-affinity programmed death receptor-1 (PD-1) monoclonal IgG4 antibody that blocks PD-1/PD-L1-mediated T-cell suppression. Cemiplimab Chemical Structure
  22. GC68857 Cetrelimab

    JNJ 63723283; JNJ 3283

    Cetrelimab (JNJ 63723283; JNJ 3283) is a humanized IgG4 monoclonal antibody that targets PD-1. Cetrelimab has a Kd of 1.72 nM for binding to PD-1 (HEK293 cells). As such, Cetrelimab blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2 (with IC50 values of 111.7 ng/mL and 138.6 ng/mL, respectively). Cetrelimab also stimulates peripheral T cells, increases cytokine levels (IFN-gamma, IL-2, TNF-alpha), and inhibits tumor growth in vivo.

     Cetrelimab Chemical Structure
  23. GC74601 Cosibelimab

    CK-301; TG-1501

     Cosibelimab (CK-301; TG-1501) is a high-affinity, fully human PD-L1-blocking monoclonal antibody that binds PD-L1 and blocks its interaction with PD-1. Cosibelimab Chemical Structure
  24. GC69001 Dostarlimab

    TSR-042

    Dostarlimab (TSR-042) is a humanized monoclonal antibody against PD-1. Dostarlimab has high affinity for human PD-1 and competitively inhibits its interaction with its ligands, PD-L1 and PD-L2, with IC50s of 1.8 nM and 1.5 nM, respectively.

     Dostarlimab Chemical Structure
  25. GC35913 Durvalumab

    A humanized anti-PD-L1 monoclonal antibody

     Durvalumab Chemical Structure
  26. GC66344 Envafolimab

    ASC 22; KN 035

     Envafolimab (ASC 22; KN 035) is a recombinant protein of a humanized single-domain anti- PD-L1 antibody. Envafolimab is created by a fusion of the of anti-PD-L1 domain with Fc fragment of human IgG1 antibody. Envafolimab blocks interaction between PD-L1 and PD-1 with an IC50 value of 5.25nm. Envafolimab shows antitumor activity. Envafolimab has the potential for the research of solid tumors. Envafolimab Chemical Structure
  27. GC74543 Ezabenlimab

    BI-754091

     Ezabenlimab (BI-754091) is an anti-PD-1 mAb with binding constant Kd value of 6 nM (CHO cells). Ezabenlimab Chemical Structure
  28. GC38044 Fraxinellone Fraxinellone Chemical Structure
  29. GC74553 Geptanolimab

    APL-501; CBT-501; GB-226

     Geptanolimab (CBT-501) is a humanized IgG4k monoclonal antibody against programmed death-1 (PD-1). Geptanolimab Chemical Structure
  30. GC74556 Gilvetmab Gilvetmab is a potent caninized antiPD-1 monoclonal antibody. gilvetmab blocks the interaction between PD-1 and its ligand PDL-1. Gilvetmab Chemical Structure
  31. GC68404 Human PD-L1 inhibitor IV Human PD-L1 inhibitor IV Chemical Structure
  32. GC74564 Ivonescimab

    AK112

     Ivonescimab (AK112) is a PD-1/VEGF Bispecific Antibody. Ivonescimab Chemical Structure
  33. GC74568 Latikafusp

    AMG 256

     Latikafusp (AMG 256) is a bifunctional fusion protein comprising a PD-1-targeting antibody and IL-21 mutein designed to deliver IL-21 pathway stimulation to PD-1+ cells. Latikafusp Chemical Structure
  34. GC73220 LSD1-IN-24 LSD1-IN-24(compound 3S) is a selective LSD1 inhibitor with IC50 = 0.247 μM. LSD1-IN-24 Chemical Structure
  35. GC73549 LSD1-IN-27 LSD1-IN-27 (Compound 5ac) is a LSD1 inhibitor (IC50: 13 nM). LSD1-IN-27 Chemical Structure
  36. GC69677 MAX-10181

    PD-1/PD-L1-IN-30

    MAX-10181 (PD-1/PD-L1-IN-30) is a PD-1/PD-L1 binding inhibitor with an IC50 value of 0.018 μM. MAX-10181 can be used for research on cancer and other related diseases.

     MAX-10181 Chemical Structure
  37. GC34218 Nivolumab (BMS-936558)

    BMS-936558, ONO-4538, MDX-1106

     Nivolumab, an anti-cancer monoclonal antibody, is a programmed death receptor-1 blocking human IgG4 antibody to treat advanced (metastatic) non-small cell lung cancer. Nivolumab (BMS-936558) Chemical Structure
  38. GC74583 Nofazinlimab

    CS1003

     Nofazinlimab (CS1003) is a humanised IgG4 anti-PD-1 monoclonal antibody. Nofazinlimab Chemical Structure
  39. GC36767 NP-12

    AUR-012, SNTSESFK(SNTSESF)FRVTQLAPKAQIKE-NH2

     NP-12 (NP-12) is a peptide antagonist of the PD-1 signaling pathway, displays equipotent antagonism toward PD-L1 and PD-L2 in rescue of lymphocyte proliferation and effector functions. NP-12 exhibits immune activation, excellent antitumor activity, and potential for better management of immune-related adverse events (irAEs). NP-12 Chemical Structure
  40. GC36768 NP-12 (TFA) NP-12 (TFA) Chemical Structure
  41. GC65266 Onvatilimab Onvatilimab (JNJ-61610588) is a human IgG1κ anti-VISTA (V-domain Ig Suppressor of T-cell Activation) monoclonal antibody. Onvatilimab has an anti-tumor activity. Onvatilimab Chemical Structure
  42. GC74592 Pacmilimab

    CX-072

     Pacmilimab (CX-072) is a potent PD-L1 inhibitor. Pacmilimab Chemical Structure
  43. GC19225 PD-1-IN-1 (CA-170)

    CA-170

     PD-1-IN-1 (CA-170) is an orally active dual inhibitor of the immune checkpoint regulatory proteins VISTA and PD-L1. PD-1-IN-1 (CA-170) Chemical Structure
  44. GC34928 PD-1-IN-17 An inhibitor of PD-1 signaling PD-1-IN-17 Chemical Structure
  45. GC34929 PD-1-IN-17 TFA PD-1-IN-17 TFA is a programmed cell death-1 (PD-1) inhibitor extracted from patent WO2015033301A1, Compound 12, inhibits 92% splenocyte proliferation at 100 nM. PD-1-IN-17 TFA Chemical Structure
  46. GC36862 PD-1-IN-22 PD-1-IN-22 is a potent programmed cell death-1 (PD-1)/programmed cell death-ligand 1 (PD-L1) interaction inhibitor with an IC50 of 92.3 nM. PD-1-IN-22 Chemical Structure
  47. GC63517 PD-1-IN-24 PD-1-IN-24 (compound 1) is an orally active PD-1 inhibitor. PD-1-IN-24 Chemical Structure
  48. GC15142 PD-1/PD-L1 inhibitor 1 (BMS-1)

    BMS-1, Programmed Cell Death 1/Programmed Cell Death-Ligand 1 Inhibitor 1

     PD-1/PD-L1 inhibitor 1 is a PD-1/PD-L1 interaction inhibitor with an IC50 value between 6 and 100 nM. PD-1/PD-L1 inhibitor 1 (BMS-1) Chemical Structure
  49. GC16258 PD-1/PD-L1 Inhibitor 3 PD-1/PD-L1 Inhibitor 3, a macrocyclic peptide, is a potent and selective inhibitor of the PD-1/PD-L1 and CD80/PD-L1 interactions extracted from patent WO2014151634A1, compound No.1. PD-1/PD-L1 Inhibitor 3 interferes with PD-L1 binding to PD-1 and CD80 by binding to PD-L1, with IC50s of 5.60 nM and 7.04 nM, respectively. PD-1/PD-L1 Inhibitor 3 can be used for the research of various diseases, including cancer and infectious diseases. PD-1/PD-L1 Inhibitor 3 Chemical Structure
  50. GC65071 PD-1/PD-L1-IN 3 TFA PD-1/PD-L1-IN 3 TFA, a macrocyclic peptide, is a potent and selective inhibitor of the PD-1/PD-L1 and CD80/PD-L1 interactions extracted from patent WO2014151634A1, compound No.1. PD-1/PD-L1-IN 3 TFA interferes with PD-L1 binding to PD-1 and CD80 by binding to PD-L1, with IC50s of 5.60 nM and 7.04 nM, respectively. PD-1/PD-L1-IN 3 TFA can be used for the research of various diseases, including cancer and infectious diseases. PD-1/PD-L1-IN 3 TFA Chemical Structure
  51. GC62658 PD-1/PD-L1-IN 7

    PD-1/PD-L1-IN 7

     PD-1/PD-L1-IN 7 (PD-1/PD-L1-IN 7) is a human PD-1/PD-L1 protein/protein interaction inhibitor with an IC50 of 0.213 nM. PD-1/PD-L1-IN 7 Chemical Structure
  52. GC62125 PD-1/PD-L1-IN-10 PD-1/PD-L1-IN-10 (compound B2) is an orally active PD-1/PD-L1 inhibitor (IC50 of 2.7 nM) with potent anticancer efficacy. PD-1/PD-L1-IN-10 Chemical Structure
  53. GC69673 PD-1/PD-L1-IN-13

    PD-1/PD-L1-IN-13 (Compound 43) is an effective immune checkpoint PD-1/PD-L1 inhibitor, with an IC50 value of 10.2 nM for the interaction between PD-1/PD-L1. PD-1/PD-L1-IN-13 promotes CD8+ T cell activation and delays tumor growth in Hepa1-6 mouse models.

     PD-1/PD-L1-IN-13 Chemical Structure
  54. GC69674 PD-1/PD-L1-IN-14

    PD-1/PD-L1-IN-14 (compound 17) is an inhibitor of the interaction between PD-1 and PD-L1, with an IC50 value of 27.8 nM. PD-1/PD-L1-IN-14 (compound 17) inhibits the interaction between PD-1 and PD-L1, promotes dimerization, endocytosis, and degradation of PD-L1.

     PD-1/PD-L1-IN-14 Chemical Structure
  55. GC64855 PD-1/PD-L1-IN-23 PD-1/PD-L1-IN-23 is a potent and orally active inhibitor of PD-1/PD-L1. PD-1/PD-L1-IN-23 is an ester prodrug of L7. L7 is a benzo[c][1,2,5]oxadiazole derivative and biologically evaluated as inhibitors of PD-L1. PD-1/PD-L1-IN-23 displays significant antitumor effects in tumor models of syngeneic and PD-L1 humanized mice. PD-1/PD-L1-IN-23 Chemical Structure
  56. GC69676 PD-1/PD-L1-IN-29

    PD-1/PD-L1-IN-29 (S4-1) is an effective PD-1/PD-L1 inhibitor with an IC50 value of 6.1 nM. PD-1/PD-L1-IN-29 can bind to PD-L1 and disrupt the interaction between PD-1 and PD-L1, inducing dimerization and internalization of PD-L1, improving its localization in the endoplasmic reticulum, and promoting entry into the endoplasmic reticulum. PD- 1/PD-LI-IN -29 has anti-cancer activity.

     PD-1/PD-L1-IN-29 Chemical Structure
  57. GC62688 PD-1/PD-L1-IN-8

    PD-1/PD-L1-IN-8

     PD-1/PD-L1-IN-8 (PD-1/PD-L1-IN-8; example 24) is a PD-1/PD-L1 inhibitor, with an IC50 <= 10 nM. PD-1/PD-L1-IN-8 Chemical Structure
  58. GC62387 PD-1/PD-L1-IN-9 PD-1/PD-L1-IN-9 is a potent and orally active inhibitor of PD-1/PD-L1 interaction, with an IC50 of 3.8 nM. PD-1/PD-L1-IN-9 can enhance the killing activity of tumor cells by immune cells. PD-1/PD-L1-IN-9 also exhibits significant in vivo antitumor activity in a CT26 mouse model. PD-1/PD-L1-IN-9 Chemical Structure
  59. GC67694 PD-1/PD-L1-IN-9 hydrochloride PD-1/PD-L1-IN-9 hydrochloride Chemical Structure
  60. GC62502 PD-1/PD-L1-IN-NP19 PD-1/PD-L1-IN-NP19 is a PD-1/PD-L1 inhibitor, with an IC50 of 12.5 nM for human PD-1/PD-L1 interaction. PD-1/PD-L1-IN-NP19 Chemical Structure
  61. GC63984 PD-L1-IN-1 PD-L1-IN-1 is a potent PD-L1 inhibitor with an IC50 of 115 nM. PD-L1-IN-1 strongly binds with the PD-L1 protein and challenged it in a co-culture of PD-L1 expressing cancer cells (PC9 and HCC827 cells) and peripheral blood mononuclear cells enhanced antitumor immune activity of the latter. PD-L1-IN-1 significantly increased interferon γ release and apoptotic induction of cancer cells, with low cytotoxicity in healthy cells. PD-L1-IN-1 Chemical Structure
  62. GC73275 PD-L1-IN-2 PD-L1-IN-2 is a potential tumor immunological agent by inhibiting PD-L1. PD-L1-IN-2 Chemical Structure
  63. GC73546 PD-L1-IN-3 PD-L1-IN-3 (Compound 4a) is a compound that targets PD-1/PD-L1, the IC50 value and EC50 value is 4.97nM and 2.70 μM for inhibit PD-L1 and Jurkat T cells, respectively. PD-L1-IN-3 Chemical Structure
  64. GC31878 PD1-IN-2 PD1-IN-2 is a PD1 signaling pathway inhibitor, which acts as an immunomodulator. PD1-IN-2 Chemical Structure
  65. GC65920 PD1-PDL1-IN 1 PD1-PDL1-IN 1 is a potent programmed cell death 1 (PD-1) inhibitor. PD1-PDL1-IN 1 is useful as immune modulator. PD1-PDL1-IN 1 Chemical Structure
  66. GC69675 PD1-PDL1-IN 1 TFA

    PD1-PDL1-IN 1 TFA (compound 16) is an effective inhibitor of programmed cell death 1 (PD-1). PD1-PDL1-IN 1 TFA can be used as an immunomodulatory agent.

     PD1-PDL1-IN 1 TFA Chemical Structure
  67. GC19531 Pembrolizumab

    Lambrolizumab; MK-3475

     Pembrolizumab, an anti–programmed death-1 monoclonal antibody, has demonstrated clinically significant anti-tumor activity with acceptable safety in patients with advanced solid cancers and was approved by the U.S. Pembrolizumab Chemical Structure
  68. GC66394 Penpulimab Penpulimab is an IgG1 backbone anti-PD-1 monoclonal antibody with antitumor activities. Penpulimab Chemical Structure
  69. GC74611 Peresolimab

    LY-3462817

     Peresolimab is a humanized IgG1-κ antibody targeting to PD-1. Peresolimab Chemical Structure
  70. GC74595 Prolgolimab

    BCD-100

     Prolgolimab (BCD-100) is a human IgG1 anti-PD-1 monoclonal antibody containing the Fc-silencing 'LALA' mutation. Prolgolimab Chemical Structure
  71. GC74623 Reozalimab

    LY3434172

     Reozalimab is a bispecific antibody targeting to PD-1/PD-L1. Reozalimab Chemical Structure
  72. GC74616 Retifanlimab Retifanlimab is an anti-programmed cell death protein 1 (anti-PD-1) monoclonal antibody (mAb). Retifanlimab Chemical Structure
  73. GC74627 Rosnilimab

    ANB030

     Rosnilimab is a humanized IgG1-κ antibody targeting to PD-1. Rosnilimab Chemical Structure
  74. GC72463 Rulonilimab Rulonilimab is a human IgG1 monoclonal antibody against PD-1 that targets, binds and inhibits PD-1 and its downstream signalling pathways with potential immune checkpoint inhibition and anti-tumour activity. Rulonilimab Chemical Structure
  75. GC66378 Serplulimab

    HLX 10

     Serplulimab (HLX 10) is humanized monoclonal anti-PD-1 antibody. Serplulimab can be used in research of small cell lung cancer. Serplulimab Chemical Structure
  76. GC74617 SHR-1701

    Retlirafusp alfa

     SHR-1701 (Retlirafusp alfa) is a bifunctional fusion protein targeting PD-L1 and TGF-β for cancer research. SHR-1701 Chemical Structure
  77. GC65290 Sintilimab Sintilimab (IBI308) is a fully human IgG4 monoclonal antibody that binds to PD-1, thereby blocking the interaction of PD-1 with its ligands (PD-L1 and PL-L2) and consequently helping to restore the endogenous antitumour T-cell response. Sintilimab Chemical Structure
  78. GC74541 Socazolimab

    ZKAB001; STI-1014; STI-A1014

     Socazolimab (ZKAB001) is an anti-PD-L1 monoclonal antibody. Socazolimab Chemical Structure
  79. GC69934 Spartalizumab

    PDR001

    Spartalizumab (PDR001) is a humanized monoclonal antibody that binds to PD-1 with high affinity and blocks its interaction with PD-L1 and PD-L2. It can be used for the study of anaplastic thyroid cancer (ATC).

     Spartalizumab Chemical Structure
  80. GC65580 Sugemalimab Sugemalimab is a fully human, full length, anti-programmed death ligand 1 (PD-L1) immunoglobulin G4 (IgG4) monoclonal antibody (mAb). Sugemalimab shows anticancer activities and can be used for non-small cell lung cancer research. Sugemalimab Chemical Structure
  81. GC10469 Sulfamethoxypyridazine long-acting sulfonamide antibiotic Sulfamethoxypyridazine Chemical Structure
  82. GC74534 Tagitanlimab

    HBM-9167; KL-A167

     Tagitanlimab (HBM-9167) is a humanized anti-PD-L1 antibody (IgG1κ type). Tagitanlimab Chemical Structure
  83. GC65033 Tislelizumab

    Tislelizumab, a monoclonal antibody with high binding affinity to the PD-1 receptor, minimizes Fcγ receptor binding on macrophages, thereby abrogating antibody-dependent phagocytosis, a mechanism of T cell clearance and potential resistance to anti-PD-1 therapy.

     Tislelizumab Chemical Structure
  84. GC19131 Tomivosertib eFT508 is a potent, highly selective, and orally bioavailable MNK1 and MNK2 inhibitor, with IC50s of 1-2 nM against both isoforms. Tomivosertib Chemical Structure
  85. GC64561 Toripalimab

    Toripalimab is the first domestic anti-tumor PD-1 antibody in China. Toripalimab is a selective, recombinant, humanized monoclonal antibody against PD-1. Toripalimab is able to bind to PD-1 and block the interaction with its ligands. Toripalimab has exhibited primary anti-tumor effects in tumors such as melanoma, lung cancer, digestive tract tumors, hepatobiliary and pancreatic tumors, neuroendocrine neoplasms, nasopharyngeal carcinoma and urothelial carcinoma.

     Toripalimab Chemical Structure
  86. GC61946 TPP-1 TPP-1 is a potent inhibitor of the?PD-1/PD-L1 interaction. TPP-1 binds specifically to PD-L1 with a high affinity (KD=95 nM). TPP-1 inhibits human tumor growth in vivo via reactivating T-cell function. TPP-1 Chemical Structure
  87. GC74532 Tuvonralimab

    PSB-205; QL1706 (iparomlimab/tuvonralimab); PBS105

     Tuvonralimab (PSB-205; QL1706) is a dual immune checkpoint blockade containing a mixture of anti-PD-1 IgG4 and anti-CTLA-4 IgG1 antibodies, Iparomlimab and Tuvonralimab. Tuvonralimab Chemical Structure
  88. GC74460 Visugromab

    CTL-002

     Visugromab (CTL-002) is a GDF-15 neutralizing IgG4 mAb. Visugromab Chemical Structure
  89. GC70137 Vudalimab

    Vudalimab is an effective PD-1 and CTLA-4 dual inhibitor, which is a fully humanized bispecific monoclonal antibody. Vudalimab targets the immune checkpoint receptors PD-1 and CTLA-4, promoting selective T cell activation against tumors.

     Vudalimab Chemical Structure
  90. GC70145 WL12

    WL12 is a specific targeted programmatic death ligand 1 (PD-L1) binding peptide. WL12 can be radiolabeled with different radioactive isotopes to produce a radiotracer for evaluating the expression of PD-L1 in tumors.

     WL12 Chemical Structure
  91. GC74462 Zimberelimab

    GLS-010; AB-122; WBP-3055

     Zimberelimab (GLS-010) is a fully human IgG4 anti-PD-1 monoclonal antibody with an EC50 of 210 pM for human PD-1. Zimberelimab Chemical Structure

90 Item(s)

per page

Set Descending Direction